Die Radiojodtherapie der funktionellen Schilddrüsenautonomie

Abstract

In contrast to the multifocal autonomy (MFA), the target dose of 150 to 200 Gy based on total thyroid volume did not result in a comparably high success rate of approximately 95% in disseminated and focal/disseminated types of thyroid autonomy. Therefore, an increase of target dose of 200 to 300 Gy is recommended. The transient FT3 increase particularly observed in FDA and DA in the first weeks following radioiodine therapy makes short-term controls of thyroid function necessary, especially in patients with cardiac risk, in order to initiate necessary therapy.

Radioiodine Therapy of Benign Thyroid Diseases

“…When studies conducted by various researchers are evaluated together, the efficacy of radioactive iodine treatment in solitary toxic nodular goitre was determined to be 85-100% and it has been reported that hypothyroidism develops by 10-20% after treatment. considering the incidence of late recurrence, the success of radioactive iodine therapy has been reported to be higher in by surgery [41,[47][48][49][50][51][52][53]. The success rate in toxic multinodular and toxic diffuse goiter patients using different dosing protocols were reported as 92% [37,38,54].…”